- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Neumora Therapeutics Inc (NMRA)
"Neumora Therapeutics Inc stock price live, this page displays NASDAQ NMRA stock exchange data. View the NMRA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Neumora Therapeutics Inc real time stock price chart below.
What Is the Neumora Therapeutics Inc Stock Price Today?
The Neumora Therapeutics Inc stock price today is 0.70.
What Is the Stock Symbol for Neumora Therapeutics Inc?
The stock symbol for Neumora Therapeutics Inc is ""NMRA.""
What Stock Exchange Does Neumora Therapeutics Inc Trade On?
Neumora Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Neumora Therapeutics Inc a Good Stock to Buy?
Determining whether Neumora Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NMRA quote. (ISIN: US6409791000)"
What Is the Neumora Therapeutics Inc Stock Price Today?
The Neumora Therapeutics Inc stock price today is 0.70.
What Is the Stock Symbol for Neumora Therapeutics Inc?
The stock symbol for Neumora Therapeutics Inc is ""NMRA.""
What Stock Exchange Does Neumora Therapeutics Inc Trade On?
Neumora Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Neumora Therapeutics Inc a Good Stock to Buy?
Determining whether Neumora Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NMRA quote. (ISIN: US6409791000)"
NASDAQ
Currency in USD
0.70
+0.04(+5.38%)
Closed·
After Hours
0.68-0.02(-2.86%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.65
0.72
52 wk Range
0.61
17.19
NMRA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NMRA is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.650.72
52 wk Range
0.6117.19
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NMRA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Neutral
Price Target
6.29
Upside
+798.57%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
No news in this category
Looks like there are no results in this news category
Neumora Therapeutics Inc Company Profile
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease. In addition, the company’s preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Neumora Therapeutics Inc SWOT Analysis
Depression Breakthrough | Neumora's navacaprant shows promise in Phase III trials for Major Depressive Disorder, potentially tapping into a multi-billion dollar market |
Financial Health | Strong balance sheet with more cash than debt provides crucial runway for drug development, despite current weak profit margins |
Competitive Edge | Explore how Neumora's navacaprant may outperform competitors like Johnson & Johnson's aticaprant in the evolving MDD treatment landscape |
Market Sentiment | Analysts rate NMRA as "Outperform" with price targets ranging from $15 to $30, suggesting potential for significant valuation uplift |
Compare NMRA to Peers and Sector
Metrics to compare | NMRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNMRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −0.5x | −0.5x | |
PEG Ratio | −0.01 | −0.01 | 0.00 | |
Price/Book | 0.5x | −0.1x | 2.6x | |
Price / LTM Sales | - | 2.0x | 2.9x | |
Upside (Analyst Target) | - | 256.1% | 45.8% | |
Fair Value Upside | Unlock | 2.7% | 8.6% | Unlock |
Analyst Ratings
3 Buy
5 Hold
1 Sell
Ratings:
9 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 6.29
(+798.57% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.42 / -0.46
Revenue / Forecast
-- / --
FAQ
What Is the Neumora Therapeutics (NMRA) Stock Price Today?
The Neumora Therapeutics stock price today is 0.70
What Stock Exchange Does Neumora Therapeutics Trade On?
Neumora Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Neumora Therapeutics?
The stock symbol for Neumora Therapeutics is "NMRA."
What Is the Neumora Therapeutics Market Cap?
As of today, Neumora Therapeutics market cap is 107.69M.
What Is Neumora Therapeutics's Earnings Per Share (TTM)?
The Neumora Therapeutics EPS (TTM) is -1.61.
From a Technical Analysis Perspective, Is NMRA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.